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Abstract
Background: The purpose of this study was to estimate the secondary cancer risk of thyroid 
in standard radiotherapy methods which are commonly used for breast cancer patients. 
Methods: A total of 64 breast cancer patients (their age range was around 50 years old) who 
referred to Seyed-Al-Shohada hospital (Isfahan, Iran) were included in this study. The radiotherapy 
of the mentioned patients was performed using 6-MV photon beams. Dose measurements were also 
done using thermoluminescent dosimeters. Calculation of the risk of developing secondary cancer in 
thyroid was done using the Biological Effects of Ionizing Radiation Committee VII and recommended 
quantity of the International Radiation Protection Commission, excess relative risk. Results: The 
mean radiation dose to thyroid for the tangential beams, tangential field with supraclavicular (SC) 
field, and also a tangential field with SC field in modified radical mastectomy (MRM) were 
0.883 ± 0.472, 1.512 ± 0.365, and 1.587 ± 0.37, respectively. The risk of developing secondary 
thyroid cancer over a period of 5 years after breast cancer therapy in the tangential, tangential with 
a SC field, and also tangential beam with SC field in MRM were 9.974 ± 4.318, 17.891 ± 0.365, 
and 18.783 ± 4.384, respectively. The mean of the measured thyroid doses in patients treated with 
tangent fields was significantly lower than the patients under the irradiation of the tangent fields with 
SC field (P < 0.001). Conclusions: Using radiation protection equipment is suggested for breast 
cancer patients who treated with the studied radiotherapy methods.
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Introduction
Breast cancer is one of the most 
common malignancies, which are 
more prevalent in the developing 
countries.[1] The annual rate of incidence 
of breast cancer risk is approximately 
1 million worldwide.[1-3] Radiation therapy 
is one of the most common approaches to 
treat breast cancer treatment.[4] In external 
radiation therapy, healthy tissue outside 
the radiation field is inevitably exposed 
to out of field radiation. The imposed 
dose in this region is called peripheral 
dose (PD).[5,6] The PD sources are leakage 
and scattered radiation from the linac head 
and scattered radiation from the irradiated 
volume of patient.[7,8] The goal of the 
treatment planning process is to deliver 
prescribed dose to the target volume and 
to limit the organ at risk dose.[9,10] The 
absorbed dose of out of field tissues is not 
respected in treatment planning because 
of the limitation of treatment planning 
systems (TPS) in the calculation of the 
accurate dose in out of field region and 
also the lack of tomographic images of 
this region in routine imaging prescription. 
The ability of several TPS inaccurate dose 
calculation is limited to 3 cm out of field 
region.[11] Therefore, the estimation of 
the risk of developing secondary cancers 
after radiotherapy was the goal of several 
studies.[12] The risk of developing secondary 
cancer in patients who undergone radiation 
therapy has long been known.[8] Several 
studies have shown that women with breast 
cancer have an additional risk for other 
cancers such as thyroid cancer.[12-14] Many 
studies evaluated the risk of secondary 
cancer in radiotherapy of breast cancer 
patients and also a great variety can be 
seen in their methodology (measurement[15] 
or calculation[16]), dosimetry mediums 
(phantom[17,18] or patient[19]), dosimeters 
(thermoluminescent dosimeter [TLD], 
metal-oxide-semiconductor field-effect 
transistor or other types),[13,17,20] treatment 
techniques (standard or complex),[17,18] type 
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of treatment machines, reported quantity (medium dose, 
equivalent dose, and skin dose),[20-22] and the risk models 
(International Radiation Protection Commission [ICRP] or 
biological effects of ionizing radiation [BEIR]).[18,23]
The results of many studies have indicated that this risk 
cannot be ignored.[15] A number of studies demonstrated 
different radiation dose for thyroid in the mentioned patients 
who were treated with different methods. The results of 
an in vivo study on 23 patients, who underwent breast 
radiotherapy using tangential and supraclavicular (SC) fields, 
shown the thyroid dose were 2 and 8% of the prescribed 
dose, respectively.[13] In another study, the skin entrance 
dose (SED) of thyroid following breast radiotherapy was 
7% of the prescribed dose for SC field, which was more 
than thyroid’s tolerance.[17] In another study on 69 patients, 
the mean reported thyroid doses were 3.7% of the delivered 
dose measured by the TLD. The results of this study 
indicate a significant risk of thyroid cancer after breast 
radiotherapy and the need for thyroid protection especially 
for young patients.[21] Thyroid absorbed dose in out of breast 
radiotherapy fields depends on the field size and distance from 
field border. Therefore, thyroid dose differs in radiotherapy 
with different treatment plans and treatment machines. The 
purpose of this study was to measure the absorbed dose 
of thyroid and estimate the risk of its secondary cancer in 
breast cancer patients who treated with different radiotherapy 
techniques including the following: tangential beams, 
tangential with SC fields, and also a tangential field with SC 
field in modified radical mastectomy (MRM), using 6-MV 
photon beams of an ELECTA linear accelerator.
Materials and Methods
A total of 64 breast cancer patients who referred to 
Seyed-Al-Shohada Hospital (Isfahan, Iran) were included in 
this study. The TiGRT (Linatech company) TPS was used to 
design the treatment plans. The planning target volume and 
the organs at risk were specified by a radiation oncologist. 
The prescribed dose of tumor for each patient was 50 Gy 
in 25 fractions. The standard treatment plans of the selected 
patients classified in two groups as follows: (1) whole 
breast irradiation with two tangential field techniques (Tan) 
and (2) two tangential field plus two SC lymph node 
fields technique (Tan + SCL). About 64 evaluated patients, 
29 patients with mean age of 42.34 ± 6.48 were treated with 
Tan plan, 35 patients with a mean age of 43.94 ± 5.63 and 
also 34 mastectomy patients a mean age of 42.18 ± 5.52 
were treated with Tan + SCL plan. Summary of the 
treatment plans characteristics is shown in Table 1. The 
selected patients were chosen according to the following 
criteria: the patients younger than 50 were selected for 
the study, because of the longer lifespan of younger 
patients.[24-26] Considering the high dependence of PD on 
the distance from the radiation field,[22] another criterion 
for patient selection was the distance between the thyroid 
and the irradiated breast, which was determined using 
computed tomographic images of the patients. The distance 
between the upper limit of the breast and the lower limit 
of the thyroid gland was measured as the thyroid distance 
from the breast. Dose measurements were performed using 
LiF Thermoluminescence dosimeters LiF (TLD-100). Kry 
has reported that TLD-100 is well suited for measuring 
out-of-field dose at 6 MV.[27] TLDs were read out using a 
SOLARO-2A Model TLD reader (NE company) according 
to the protocol suggested by manufacturer. TLDs were 
calibrated with 6-MV beams of ELECTA linac. The thyroid 
dose measurements were performed for each patient at three 
locations specified by a radiation oncologist. According to 
the Schneider et al., the average dose can be considered 
as an average thyroid dose.[23] Therefore, three TLDs were 
located in the middle of the two right and left lobes and in 
the middle of the thyroid. The average of these three dose 
values was considered as thyroid dose for risk calculation.
To calculate the radiation-induced second thyroid cancer, 
the BEIR committee cancer incidence model was used. The 
BEIR VII model provides organ-specific parameters for 
each sex and includes a parameter relating cancer incidence 
risk with age at exposure and attained age. Equation (1) is 
the BEIR VII model for both excess relative risk (ERR) 
and excess absolute risk. In this equation, D is radiation 
absorbed dose; β
S
, γ, and η are organ-specific parameters 
for each sex; e is age at exposure; e* = (e − 30)/10 for 
e < 30 and 0 for e > 30 years; and a is the attained age.
The thyroid-specific parameters of the model (β
S
, γ, and η) 
are presented in Table 2.
sERR and EAR = ( *)
60





The ERR of secondary thyroid cancer for 5, 10, and 
15 years after breast radiotherapy was calculated using the 
Table 1: Summary of the treatment plans characteristics 
used for breast radiotherapy of evaluated patients
Treatment 
planning





Middle field 20.7×15.3 292.9 2500
Lateral field 20.1×15.5 121.8 2500
Tan + SCL
Middle field 16.8×11.8 49 2500
Lateral field 17.4×11.2 220.3 2500
Anterior field 14.6×5.8 3.9 3750
Posterior field 14.6×7.0 183.9 1250
SCL – Supraclavicular lymph node
Table 2: Thyroid‑specific parameters of biological 
effected of ionizing radiation committee VII risk 
model (1)
Location of cancer γ βM βF η
Thyroid −0.3 0.45 0.27 −2.8
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measured average dose values of thyroid in each breast 
treatment plans and equation.[1] 
Statistical analysis in this study was performed using 
SPSS (ver 20) software. The statistical tests selection was 
performed based on the type of our variables and their 
probable dependence. The one-way ANOVA test was 
applied on age-related data and thyroid doses in three 
different thyroid lobes. The post hoc test (Tukey HSD) 
was used to compare the average dose values of three 
different lobes of the thyroid. To find any dependency of 
mean thyroid dose on the side of the irradiated breast, the 
independent t-test is used.
Results
Table 3 indicates the mean thyroid doses in the evaluated 
patients who were included in this study. Table 3 also 
illustrates the results of the thyroid dose measurements for 
the mastectomy patients.
Table 3, compares the measured radiation dose for thyroid 
among left and right breast cancer patients. The percentage 
of patients with right breast cancer with Tan and Tan+SCL 
plans were 58.6% and 62.9%, respectively. The number of 
mastectomy patients with right and left breast cancer was 
equal in this study.
Table 4, indicates the dependent Variable: Relationship of 
mean measured dose of thyroid and treatment plan (Tan or 
Tan+SCL or MRM) (Tukey HSD).
The results of average thyroid dose values against the 
distance of thyroid from SC field, is illustrated in Figure 1. 
Because of the field size dependence of PD, the thyroid 
dose values of irradiated patients with 10×10 cm2 equivalent 
field size, are shown in this Figure 2.
Figure 3 shows the ERR data of developing secondary 
thyroid cancer following breast cancer radiotherapy with 
different treatments.
Discussion
The aim of this study was to measure thyroid doses and 
to estimate the risk of developing secondary cancers of the 
thyroid after breast cancer radiation therapy. The thyroid is 
a radiosensitive organ, and there are a lot of evidence for 
the incidence of radiation-induced cancer in radiotherapy 
patients. According to the Radiation Therapy Oncology 
Group report, to reduce thyroid damage, the maximum 
thyroid dose should be kept below 3% of the prescribed 
dose.[15,17] For this reason, our study aimed to evaluate 
the thyroid risk in breast cancer patients who underwent 
radiotherapy in Seyed-Al-Shohada Hospital at Isfahan.
Many studies have been conducted on the incidence of 
thyroid secondary cancer in breast cancer when is treated 
with radiation. Among several studies aimed to measure the 
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Figure 1: Thyroid dose as a function of the distance of thyroid from the 






















Figure 3: Excess relative risk of secondary thyroid cancer following breast 
radiation therapy with different plans
approximately similar treatment plans and methodology 
were selected for comparison. Vlachopoulou et al. reported 
thyroid dose, using metal-oxide-semiconductor field-effect 
transistor, 8% ± 2% and 2% ± 0.8% of the prescribed 
dose, following three-dimensional conformal radiotherapy 
of breast with and without SCL field, respectively. The 
relevant risk of secondary thyroid cancer of obtained 
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thyroid dose is calculated using the ICRP 103 risk model 
1% and 0.3%, respectively.[13] Farhood et al. reported 
SED 7% of the prescribed dose in one fraction in patients 
undergoing breast treating with Tan and SC plans using 
TLD.[17] In another study, the mean reported thyroid dose in 
69 patients undergoing radiation therapy for breast cancer 
using TLD was 3.7% of the prescribed dose, which is 
consistent with 3.02% measured in our study.[21] In a study 
by Donovan et al., thyroid dose in an anthropomorphic 
phantom under breast radiotherapy with Tan plan using 
TLD was reported 0.3% of the delivered dose against 
1.76% measured in our study.[16] Our findings verify the 
dependency of the thyroid dose on the distance of the 
thyroid from the field edge. The highest and lowest thyroid 
dose values were measured 3.17 cGy in SC field and 
0.29 cGy in Tan field, respectively. The major contribution 
of SCL fields in thyroid dose is due to the less distance 
of the thyroid to SC field edge. The dose near the field 
edge is found higher [Figure 2] which may be due to the 
penumbra of the primary beam,[28] the steep variation of 
thyroid dose with distance from the field edge is related 
to rapid attenuation of scattered radiation within the 
patient.[29] By performing one-way ANOVA on age-related 
data and thyroid doses in three different thyroid lobes, 
we concluded that the mean age of the patients was the 
same in three evaluated groups (P = 0.394). The average 
dose values of three different lobes of the thyroid were 
significantly different between three groups (P < 0.001). 
The results of the post hoc test (Tukey HSD) show that the 
mean measured dose of thyroid in patients treated with Tan 
plan was significantly lower than in patients undergoing 
Tan + SCL plans (P < 0.001) which is in confirmation with 
Vlachopoulou et al. finding.[13] The proximity of the thyroid 
to the SC fields and high dependency of PD to distance 
from field edge could be the cause of this difference. 
Comparison of the average thyroid dose in patients 
undergoing breast-saving and mastectomy surgery against 
who had treated with the same Tan + SCL plan, does not 
show any significant difference (P = 0.667).
Independent t-test results indicate that the measured mean 
thyroid dose is independent on the side of the irradiated 
breast (P = 0.53). According to BEIR VII and ICRP 
reports, the radiation-induced secondary cancer more likely 
incidence during <10 years after radiotherapy.
Conclusions
In this study, the imposed dose of thyroid and the risk of 
its secondary cancer in breast cancer patients who treated 
with tangential beams, tangential with SC field, and 
also tangential field with SC field in MRM plans were 
evaluated.
Based on the results of this study, to reduce the risk 
of secondary thyroid cancer in a patient treated with 
radiotherapy technique for breast cancer, protection of the 
thyroid gland is necessary.
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